is an associate in the Litigation Practice Group in the Houston office of Haynes Boone. Prior to becoming a lawyer, Mini worked for many years in genetics and genomics at The University of Texas M.D. Anderson Cancer Center, where she conducted research under several national grants. She has published many articles in peer-reviewed scientific journals and has presented frequently at scientific meetings and conferences in the United States and Europe.
The Federal Circuit held that Mylan Pharmaceuticals, Inc. (“Mylan”), a generic drug manufacturer, was subject to specific personal jurisdiction in Delaware because Mylan had filed an abbreviated new drug application (“ANDA”) and “contemplate[d] plans to engage in marketing of the proposed generic drugs” in the state. The ruling affirmed two different decisions by judges in the United States District Court for the District of Delaware that Mylan was subject to specific jurisdiction in Delaware. However, as noted below, it looks like Mylan intends to seek panel or en banc rehearing and possibly pursue a petition for certiorari if the Federal Circuit does not grant the rehearing or re-hears the case and continues to find personal jurisdiction.